Jay T. Foust
Keine laufenden Positionen mehr
Profil
Jay T.
Foust served as Chairman at Cantex Pharmaceuticals, Inc. and as Director at RCT BioVentures.
He obtained an undergraduate degree from the University of Arizona in 2000.
Ehemalige bekannte Positionen von Jay T. Foust
| Unternehmen | Position | Ende |
|---|---|---|
Cantex Pharmaceuticals, Inc.
 Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cantex Pharmaceuticals, Inc. develops heparin to ameliorate cardiac ischemia-reperfusion injuries. It also develops medications to enhance the safety and effectiveness of existing cancer treatments. The firm provides Disulfiram + copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions. The company was founded in 2013 by Thomas P. Kennedy, Neil William Flanzraich and Stephen G. Marcus and is headquartered in Weston, FL. | Vorsitzender | - |
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Corporate Officer/Principal | - |
Ausbildung von Jay T. Foust
| University of Arizona | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures (RCT BioVentures) is a venture capital subsidiary of Research Corporation Technologies Inc founded in 1987. The firm is headquartered in Tucson, Arizona. | Finance |
Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cantex Pharmaceuticals, Inc. develops heparin to ameliorate cardiac ischemia-reperfusion injuries. It also develops medications to enhance the safety and effectiveness of existing cancer treatments. The firm provides Disulfiram + copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions. The company was founded in 2013 by Thomas P. Kennedy, Neil William Flanzraich and Stephen G. Marcus and is headquartered in Weston, FL. | Health Technology |
